Ignite Creation Date:
2024-05-06 @ 8:22 PM
Last Modification Date:
2024-10-26 @ 3:26 PM
Study NCT ID:
NCT06353646
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-04-09
First Post:
2024-03-28
Brief Title:
XH001 Combination With Ipilimumab and Chemotherapy for Patients With Resected Pancreatic Cancer
Sponsor:
Wu Wenming
Organization:
Peking Union Medical College Hospital
Study Overview
Official Title:
Efficacy and Safety Trial of XH001 Neoantigen Cancer Vaccine Sequential Combination With Ipilimumab and Chemotherapy for Patients With Resected Pancreatic Cancer
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a single-center open label single-arm investigator-initiated study to evaluate the efficacy and safety of XH001 neoantigen cancer vaccine sequential combination with ipilimumab and chemotherapy in pancreatic cancer patients following surgical resection
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None